Launching a cosmetic product in the United States does not end the compliance process once the product reaches consumers. Brands also need systems for monitoring complaints, identifying potential safety concerns, assessing adverse events, maintaining records, and making required reports to the FDA.
This is where MoCRA adverse event reporting becomes particularly important.
The Modernization of Cosmetics Regulation Act of 2022 introduced mandatory reporting requirements for serious adverse events associated with cosmetic products. The obligation sits with the cosmetic product’s responsible person, making it important for brands to understand exactly what qualifies, when the reporting clock starts, and who must take action.
For international brands entering the US market, adverse event management should therefore be treated as part of the wider compliance framework rather than as a separate administrative task.
مراجعة: راج ناران - الشريك المؤسس والرئيس التنفيذي لمجموعة GCRS
النقاط الرئيسية
- Under MoCRA, a serious adverse event associated with a cosmetic product must be reported to the FDA by the responsible person.
- The reporting deadline is 15 business days after the responsible person receives the report of the serious adverse event.
- Serious events can include hospitalisation, life-threatening experiences, death, significant disfigurement, infection, persistent or significant disability, and certain other serious outcomes.
- A copy of the product label must be included with the serious adverse event report.
- New medical or other information received within one year of the initial report must also be submitted within 15 business days.
- Adverse event records generally need to be maintained for six years, with a shorter retention period applying to certain qualifying small businesses.
- A structured adverse event process helps brands respond quickly, maintain documentation, and support ongoing MoCRA compliance.
What Is an Adverse Event Under MoCRA?
An adverse event is a health-related event associated with the use of a cosmetic product that is adverse.
Not every consumer complaint will automatically qualify as a serious adverse event requiring mandatory FDA reporting.
The important distinction is whether the event meets the statutory definition of a serious adverse event.
For example, a consumer may report irritation, redness, discomfort, or another unwanted reaction. The business needs a process for capturing and assessing these complaints so that potentially serious cases are identified and escalated appropriately.
This means brands should not rely solely on the wording used by a consumer. The circumstances, outcome, medical treatment and severity of the event may all be relevant when assessing whether the reporting threshold has been met.
What Counts as a Serious Adverse Event?
MoCRA defines a serious adverse event using specific outcomes.
A cosmetic-related event can qualify when it results in:
- Death
- A life-threatening experience
- Inpatient hospitalisation
- Persistent or significant disability or incapacity
- A congenital anomaly or birth defect
- An infection
- Significant disfigurement
Significant disfigurement can include serious and persistent rashes, second or third-degree burns, significant hair loss, or a persistent or significant alteration in appearance that is not intended under customary or usual conditions of use.
An event may also qualify when reasonable medical judgment determines that medical or surgical intervention was required to prevent one of these serious outcomes.
Examples of Cases That May Require Escalation
Consider a few practical scenarios:
Example 1: Serious burn
A consumer uses a cosmetic product and develops a second-degree burn that requires medical treatment. This may meet the serious adverse event definition.
Example 2: Hospitalisation
A consumer experiences a severe reaction associated with use of a cosmetic product and is admitted to hospital. The event may qualify as a serious adverse event.
Example 3: Mild, short-term irritation
A consumer experiences temporary redness that resolves without significant medical intervention or a serious outcome. This would not automatically meet the MoCRA serious adverse event definition.
The assessment should always be based on the facts of the case and the applicable legal definition rather than assumptions about the product or the complaint.
Is Every Cosmetic Complaint Reportable to the FDA?
No.
MoCRA specifically requires responsible persons to report serious adverse events associated with cosmetic products to the FDA.
Non-serious adverse events are not subject to the same mandatory FDA reporting requirement under MoCRA. However, the FDA allows non-serious cosmetic adverse events to be submitted voluntarily.
This distinction is important because brands still need an effective complaint-handling system even when a particular complaint does not require mandatory FDA reporting.
A robust system should capture complaints consistently, assess their severity, identify trends and retain supporting documentation.
This is where خدمات الامتثال can add value by connecting complaint handling with the wider product safety and regulatory framework.
What Is the MoCRA Adverse Event Reporting Deadline?
The deadline for reporting a serious adverse event is 15 business days.
The 15-business-day period begins when the responsible person receives the report of the serious adverse event.
The responsible person must submit the required information to the FDA and include a copy of the product label appearing on or within the retail packaging.
This makes response time critical.
A company that waits until the end of the 15-business-day period to begin investigating a potentially serious complaint may leave little time to gather the relevant information, assess the event and prepare the submission.
For this reason, brands should establish internal escalation procedures before an adverse event occurs.
What Happens If New Information Is Received?
The reporting obligation does not necessarily end with the initial submission.
If the responsible person receives new medical or other information about the adverse event within one year of the initial report, that new information must also be submitted to the FDA within 15 business days of receipt.
This makes ongoing case management important.
Brands should therefore maintain a process for:
- Recording the original complaint.
- Assessing the event.
- Determining whether it meets the serious adverse event threshold.
- Preparing and submitting the FDA report where required.
- Monitoring for additional information.
- Updating the FDA when qualifying new information is received.
- Maintaining the supporting records.
Who Is Responsible for Reporting?
Under MoCRA, the responsible person is the manufacturer, packer or distributor whose name appears on the cosmetic product label in accordance with the applicable federal requirements.
The responsible person has the legal obligation to report serious adverse events associated with the use of the cosmetic product in the United States.
This is particularly important for brands based outside the US.
A brand should establish clearly who holds the responsible person role for each applicable product and ensure that the person or organisation responsible for regulatory communication has access to the information needed to manage adverse events.
What Does the Responsible Person Need to Do?
The role involves more than simply submitting a form.
A responsible person should have processes that support:
- Adverse event intake
- Complaint assessment
- Seriousness determination
- Regulatory escalation
- FDA reporting
- Supporting documentation
- Follow-up information
- Record retention
- Communication with relevant internal and external stakeholders
For brands managing multiple products or markets, this can become difficult to coordinate manually.
Dedicated responsible person services can provide structured regulatory oversight and help brands manage these obligations as part of a wider compliance programme.
What Information Should Brands Capture From an Adverse Event?
The quality of the initial information can directly affect how effectively a case can be assessed.
Brands should have a consistent intake process for capturing information such as:
- Product name
- Product identifier or batch information where available
- Date of product use
- Date the event occurred
- Description of the event
- Consumer outcome
- Medical treatment or intervention
- Hospitalisation details where applicable
- Relevant product and packaging information
- Contact information for the reporter where available
- Photographs or other supporting evidence where appropriate
- Relevant medical information provided by the reporter
Not every complaint will contain complete information when first received.
The important point is to have a defined process for documenting what was reported, assessing the available information and following up where appropriate.
Why Recordkeeping Matters Under MoCRA
Adverse event reporting is not simply about meeting a reporting deadline.
The supporting records are also important because the FDA has authority to access adverse event report records during inspections.
Brands therefore need to be able to demonstrate how an adverse event was received, assessed, reported and followed up.
Record retention requirements should be incorporated into the company’s wider document control system.
For many businesses, this becomes challenging when complaints, product information, formulations, labels, safety documentation and regulatory submissions are stored across separate systems.
A centralised compliance approach can make it easier to maintain an organised audit trail.
How Compliance Automation Can Improve Adverse Event Management
As product portfolios grow, manually managing adverse event information through emails, spreadsheets and disconnected files can create unnecessary compliance risk.
Compliance automation can help establish a more structured workflow for managing regulatory information.
Depending on the system and scope, a centralised approach can help teams:
- Capture complaints consistently
- Track case status
- Assign responsibility for follow-up
- Store supporting documentation
- Maintain product and regulatory records
- Monitor reporting deadlines
- Maintain version-controlled information
- Create a clearer audit trail
Automation does not replace regulatory judgment. Instead, it can help teams organise information and reduce the risk of important actions being overlooked.
For brands operating across several markets, connecting adverse event management with the wider product compliance framework can also reduce duplication and improve visibility.
Common MoCRA Adverse Event Reporting Mistakes
Several avoidable issues can make adverse event management more difficult.
- Treating Every Complaint as Non-Serious
A complaint that initially appears minor may contain information indicating a more serious outcome. Each case should be assessed using the applicable criteria.
- Waiting Too Long to Escalate
The 15-business-day deadline means businesses need a defined internal escalation process.
- Failing to Track Follow-Up Information
New information received within one year of the initial report may trigger an additional FDA submission.
- Poor Documentation
Incomplete records can make it difficult to demonstrate how the case was assessed and managed.
- Unclear Responsibility
If the brand, distributor, importer and regulatory service provider are unclear about who is responsible for reporting, valuable time can be lost.
- Treating Adverse Event Management as a One-Off Task
MoCRA compliance is an ongoing responsibility. Complaint monitoring and adverse event management should remain part of the post-market compliance process.
How GCRS Can Support MoCRA Adverse Event Compliance
For brands selling cosmetics in the United States, adverse event reporting should sit within a broader compliance strategy.
GCRS supports brands with خدمات قانون تنظيم مستحضرات التجميل في الولايات المتحدة, including regulatory support around product listing, facility requirements, responsible person obligations, adverse event processes and supporting compliance documentation.
GCRS can also support wider product compliance activities including safety assessments, formulation reviews, testing coordination, documentation and regulatory management.
For international brands, this integrated approach can help connect US requirements with compliance activities already being managed across other markets.
GCRS can also provide responsible person services for brands that need regulatory support and representation across applicable markets.
The objective is not simply to respond when a serious complaint occurs. It is to establish a compliance structure that helps the business identify issues, manage regulatory obligations and maintain appropriate documentation throughout the product lifecycle.
A Practical MoCRA Adverse Event Reporting Checklist
Before launching or expanding a cosmetic product in the US, brands should ask:
- Have we identified the responsible person?
- Is consumer complaint contact information clearly available?
- Do we have an adverse event intake process?
- Can we distinguish serious from non-serious events?
- Do we have an escalation procedure?
- Can we identify when the 15-business-day reporting period begins?
- Can we prepare the required FDA submission?
- Can we provide the relevant product label?
- Do we have a process for monitoring follow-up information?
- Are adverse event records stored securely and systematically?
- Can we retrieve records if the FDA requests access?
- Are responsibilities clearly assigned between the brand, distributor, manufacturer and regulatory partner?
If the answer to several of these questions is no, the business may need to strengthen its post-market compliance system.
Conclusion
MoCRA adverse event reporting creates a clear post-market responsibility for cosmetic brands selling products in the United States.
The key requirement is straightforward: when a serious adverse event associated with a cosmetic product is reported to the responsible person, the event must be reported to the FDA within 15 business days. Additional medical or other information received within one year may also need to be submitted within 15 business days.
The practical challenge is building a system that allows a business to identify serious cases quickly, collect appropriate information, meet reporting deadlines and maintain reliable records.
For growing cosmetic brands, this is where regulatory expertise, structured compliance processes and أتمتة الامتثال can work together.
Selling cosmetics in the US and need help managing MoCRA requirements?
GCRS can support your brand with MoCRA compliance, adverse event processes, regulatory documentation and ongoing compliance management.
Speak to our MoCRA regulatory experts and build a compliance process designed for your US market operations.
Frequently Asked Questions
- What is the deadline for reporting a serious adverse event under MoCRA?
A responsible person must report a serious adverse event associated with a cosmetic product to the FDA within 15 business days after receiving the report. A copy of the product label must also be included.
- What counts as a serious adverse event under MoCRA?
Serious adverse events can include death, life-threatening experiences, inpatient hospitalisation, persistent or significant disability or incapacity, congenital anomalies or birth defects, infections, significant disfigurement, or cases requiring medical or surgical intervention to prevent one of these outcomes.
- Who is responsible for MoCRA adverse event reporting?
The responsible person is the manufacturer, packer or distributor whose name appears on the cosmetic product label in accordance with applicable federal requirements. The responsible person is responsible for submitting mandatory serious adverse event reports to the FDA.
- Do cosmetic brands have to report every adverse event to the FDA?
No. MoCRA requires mandatory FDA reporting for serious adverse events. Non-serious cosmetic adverse events may be submitted voluntarily, but they are not subject to the same mandatory reporting requirement.
About the Reviewer – Raj Narang
Raj Narang Co-founder and CEO of GCRS Group, supporting cosmetic, fragrance, and personal care brands with global regulatory strategy, Responsible Person Services, claims and compliance oversight, and international market entry across the UK, EU, USA, UAE, India, and wider global markets.
With over two decades of experience in regulatory affairs and compliance strategy, Raj works with brands, manufacturers, and retailers to help navigate evolving cosmetic regulations, reduce compliance risk, and support successful global product launches.
